Format

Send to:

Choose Destination
See comment in PubMed Commons below
Med Hypotheses. 2013 Oct;81(4):619-22. doi: 10.1016/j.mehy.2013.07.016. Epub 2013 Jul 26.

Palmitoylethanolamide: from endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence.

Author information

  • 1Department of Addiction, ASL CN2, Viale Coppino 46, 12051 Alba (CN), Italy. Electronic address: coppolamail@alice.it.

Abstract

Palmitoylethanolamide (PEA) is a fatty acid amide showing some pharmacodynamic similarities with Δ9-tetrahydrocannabinol, the principal psychoactive compound present in the cannabis plant. Like Δ9-tetrahydrocannabinol, PEA can produce a direct or indirect activation of cannabinoid receptors. Furthermore, it acts as an agonist at TRPV1 receptor. The hypothesis is that PEA has anti-craving effects in cannabis dependent patients, is efficacious in the treatment of withdrawal symptoms, produces a reduction of cannabis consumption and is effective in the prevention of cannabis induced neurotoxicity and neuro-psychiatric disorders.

Copyright © 2013 Elsevier Ltd. All rights reserved.

PMID:
23896215
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk